A modest stake in CORT pays for a few BSR subscriptions! Nice to win one for a change, even if Cushing's was unanticipated by this speculator!
On the fundamentals, does a hypothetically fast approval for Cushing's provide any value to the other candidates in the CORT pipeline - anti-pyschotic and anti-weight-gain-with-anti-psychotic drugs? Safety data? Off-label opportunities? I imagine not, since those molecules are going to be different,or does someone with deeper insight see something there?
News 
Market Data 
Discover 
AI
